Business
Zimmer Biomet designs and sells orthopedic implants, surgical products and related digital technologies.
Zimmer Biomet converted mid-single-digit medical-device growth into higher profit and strong free cash flow, with capital spending the main constraint on conversion.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 7.2%OK
- Profitability — Net income declined 22.0% to $705.1M from $903.8MWatch
- Cash flow — Free cash flow grew 13.7% to $1.473B from $1.296BOK
- Margins — Operating margin contracted 340 bps to 13.34%Watch
- Accounting — Profitable orthopedic growth with strong cashNote
- Insiders — 0 purchases and 6 salesNote
Where the revenue comes from
Fiscal 2025, as ZIMMER BIOMET HOLDINGS, INC. reports it. History and quarterly detail are in the app.
- Knees$3.3B
- SET$2.2B
- Hips$2.1B
- Technology And Data Bone Cement And Surgical$665.6M
Leadership changes
From ZIMMER BIOMET HOLDINGS, INC.'s own filings, the day they're filed.
- Kevin Thornal · President · appointmenteff. 2025-07-01
- Michael Farrell · Chairman · appointmenteff. 2025-05-29
- Ivan Tornos · Chairman · appointmenteff. 2025-05-29
Latest filings
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-29
- 8-K · Company announcement2026-05-27
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ZIMMER BIOMET HOLDINGS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.